In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to ...

French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing ...

MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] MaaT Pharma – Media Relations Pauline RICHAUD Senior PR ...

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg ® in acute Graft-versus Host Disease in Europe . MaaT Pharma and Clinigen signed exclusive long-term ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid ...

Libertarian Vice Presidential candidate Mike ter Maat says old habits die hard and he expects more interest following the first Presidential debate. Skip Navigation. Share on Facebook; ...

Ter Maat drove a pickup truck with a 14-foot trailer hitched to the back and stacked with goods. "He's getting phone calls while he's driving down here," Katsma said.

Kepher-Maat also gives New York-based IFC an additional presence in LA, he noted. Last year across the labels were 30 Shudder movies, 12 IFC Films and eight RLJE, not all released theatrically.

Kepher-Maat, who is based in Los Angeles, will report to Scott Shooman, the company’s executive vice president and head of a film group encompassing three brands: IFC Films, RLJE Films and Shudder.